Solid Tumors

实体瘤

• 批准号: 6433369
• 负责人: LEE J. HELMAN
• 金额: --
• 依托单位: DIVISION OF CLINICAL SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6433369
• 关键词: Ewing's tumor; T lymphocyte; alkylating agents; antigen presenting cell; cancer risk; child (0-11); clinical research; cytotoxicity; dosage; doxorubicin; human subject; human therapy evaluation; insulinlike growth factor; interview; metastasis; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer vaccine; osteosarcoma; pediatric neoplasm /cancer; rhabdomyosarcoma; sarcoma; somatostatin; somatotropin

We have closed our previous high-risk sarcoma study and are hoping to open a new study in the next year. In collaboration with several other centers, we will studying a marrow purging approach using a monoclonal antibody and quantitative real time PCR (see Dr. Mackall's report). We have just closed our OncoLar. study in recurrent osteosarcoma and are currently finalizing the data for a paper. Briefly, the data demonstrate a 50% reduction in circulating IGFI levels with no changes in IGFBP3 levels or IGFII levels, an no further IGFI reduction with the addition of tamoxifen. No objective responses were seen. We have begun a new study for newly diagnosed localized and metastatic osteosarcoma patients in collaboration with several other centers. This study will attempt to determine the value of various new imaging techniques in predicting response to neoadjuvant chemotherapy as well as to prospectively perform gene expression profiling analysis on all tumors. It will also pilot the application of high-dose alkylating agent therapy with peripheral stem cell rescue for all metastatic patients and patients who demonstrate a poor histologic response to standard neoadjuvant therapy.

我们已经结束了之前的高风险肉瘤研究，并希望在明年开展一项新的研究。 我们将与其他几个中心合作，研究使用单克隆抗体和定量实时 PCR 的骨髓净化方法（参见 Mackall 博士的报告）。 我们刚刚关闭了 OncoLar。研究复发性骨肉瘤，目前正在最终确定一篇论文的数据。 简而言之，数据表明循环 IGFI 水平降低了 50%，而 IGFBP3 水平或 IGFII 水平没有变化，添加他莫昔芬后 IGFI 没有进一步降低。 没有看到客观的回应。 我们与其他几个中心合作，开始了一项针对新诊断的局限性和转移性骨肉瘤患者的新研究。 本研究将尝试确定各种新成像技术在预测新辅助化疗反应以及前瞻性地对所有肿瘤进行基因表达谱分析方面的价值。 它还将针对所有转移性患者和对标准新辅助治疗表现出组织学反应较差的患者，试点应用高剂量烷化剂治疗和外周干细胞挽救。